KR20020046615A - Skin whitening composition containing arctium lappa extracts - Google Patents

Skin whitening composition containing arctium lappa extracts Download PDF

Info

Publication number
KR20020046615A
KR20020046615A KR1020000076871A KR20000076871A KR20020046615A KR 20020046615 A KR20020046615 A KR 20020046615A KR 1020000076871 A KR1020000076871 A KR 1020000076871A KR 20000076871 A KR20000076871 A KR 20000076871A KR 20020046615 A KR20020046615 A KR 20020046615A
Authority
KR
South Korea
Prior art keywords
extract
whitening agent
propanol
allium
water
Prior art date
Application number
KR1020000076871A
Other languages
Korean (ko)
Inventor
김성우
이강태
정지헌
조병기
Original Assignee
유상옥,송운한
주식회사 코리아나화장품
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유상옥,송운한, 주식회사 코리아나화장품 filed Critical 유상옥,송운한
Priority to KR1020000076871A priority Critical patent/KR20020046615A/en
Publication of KR20020046615A publication Critical patent/KR20020046615A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

PURPOSE: A whitening agent containing an Arctii Fructus extract as a main material is provided. By directly acting on a melanin metabolic pathway induced by α-MSH, it exhibits excellent whitening action. CONSTITUTION: This whitening agent contains 0.0001 to 50.0% by weight of an Arctii Fructus extract, based on the total dried weight of the whitening agent. The fructus of Arctium lappa is ground and soaked in a solvent at room temperature for 1 to 15 days and concentrated under reduced pressure, wherein the solvent is selected from water, lower alcohol, a mixture of water and lower alcohol, acetone, ethylacetate, 1,3-butylene glycol, hexane, diethylether, n-propanol, iso-propanol, n-butanol.

Description

우방자추출물을 함유하는 미백제{Skin whitening composition containing arctium lappa extracts}Skin whitening composition containing arctium lappa extracts}

본 발명은 우엉(Arctium lappa)의 열매로부터 분리 정제한 우방자추출물을 함유하는 미백제에 관한 것이다.The present invention relates to a whitening agent containing milkybean extract, purified from the fruit of Burdock ( Arcium lappa ).

화장료의 주요 테마 중 하나는 피부의 기미, 주근깨 등을 없애거나, 이들의 생성을 억제하여 피부를 하얗게 하는 미백 화장료이다. 최근에는 여러 식물자원 성분들이 피부생리에 미치는 영향에 대한 연구가 활발히 이루어지고 있으며, 이로부터 안정성이 우수하고, 피부미백 효과가 뛰어난 물질들이 개발되고 있다.One of the main themes of cosmetics is whitening cosmetics that whiten the skin by eliminating blemishes, freckles, etc., or suppressing their production. Recently, studies on the effects of various plant resources on skin physiology have been actively conducted. From this, materials having excellent stability and excellent skin whitening effect have been developed.

사람의 피부색은 민족, 개인, 신체부위에 따라 다르지만, 피부나 모발색을 결정하는 색소는 멜라닌이다. 멜라닌 색소는 표피 기저층에 산재하는 멜라노사이트(Melanocyte)에 있어서 아미노산의 하나인 티로신(Tyrosine)을 기본으로 멜라닌 합성효소(Tyrosinase) 작용에 의해 산화, 중합하여 만들어진다. 멜라닌은 사람의 피부색을 결정할 뿐 아니라 자외선을 흡수하고 자외선 유해작용으로부터 피부를 지키는 역할을 하지만, 자외선 노출이나 염증에 의해 피부 내에 과다하게 생성되면 색소침착 현상이 일어나 기미나 주근깨의 원인이 된다.Human skin color varies according to ethnicity, individual, and body parts, but the pigment that determines skin and hair color is melanin. Melanin pigment is made by oxidizing and polymerizing by melanin synthase (Tyrosinase) action based on one of the amino acids Tyrosine in melanocytes (Melanocyte) scattered on the basement layer of the epidermis. Melanin not only determines the color of human skin, but also absorbs ultraviolet rays and protects the skin from harmful UV rays.However, melanin can cause pigmentation and freckles when excessively generated in the skin by UV exposure or inflammation.

멜라닌 세포에서의 멜라닌 생성은 외부조건, 호르몬, 사이토카인(cytokine)등 여러가지 인자의 영향을 받는다. 이중 α-멜라노사이트 자극 호르몬 (α-MSH: α-Melanocyte stimulating hormone)은 피부색소 침착에 관여하는 중요한 호르몬으로 POMC(Proopiomelanocortin) 단백질의 단백질 가수결합에 의해 생산되며, 자외선 조사나 염증 반응시 각질형성세포(Keratinocyte)에서 분비되어 멜라노사이트에 작용함으로서 색소 침착을 유발한다. 따라서 이러한 색소 침착 현상을 막기 위해서는 멜라닌 생성과정 중 일부 과정을 조절함으로써 억제할 수가 있다.Melanin production in melanocytes is influenced by several factors, including external conditions, hormones, and cytokines. Α-Melanocyte stimulating hormone (α-MSH) is an important hormone involved in skin pigmentation and is produced by protein hydrolysis of POMC (Proopiomelanocortin) protein. It is secreted from cells (Keratinocyte) and acts on melanocytes, causing pigmentation. Therefore, in order to prevent the pigmentation phenomenon, it can be suppressed by controlling some of the melanin production process.

기존의 코직산(kojic acid), 알부틴(Arbutin), 상백피 추출물 및 감초 추출물 등과 같은 미백제들은 티로시나제의 활성을 억제하는 역할을 한다. 이와 같은 작용 기작을 갖는 물질들은 티로시나제와 직접적인 상호작용을 함으로써 효과를 나타내게 되는데, 피부세포 내로의 흡수 및 멜라노좀으로의 침투가 용이하지 않을 경우 효과가 나타나기 어렵다.Conventional whitening agents such as kojic acid (arbutin), arbutin, lettuce extract and licorice extract play a role in inhibiting the activity of tyrosinase. Substances having such a mechanism of action have an effect by directly interacting with tyrosinase, and it is difficult to show an effect when absorption into skin cells and penetration into melanosomes are not easy.

따라서, 본 발명자들은 기존의 멜라닌 합성효소의 활성만을 저해하는 물질에 비하여 보다 효과적으로 미백 작용을 나타낼 수 있는 미백 화장료 조성물을 개발하고자 노력하였다. 결과, 우방자 추출물이 α-MSH에 의해 유발되는 멜라닌 대사 경로에 직접 작용함으로써 멜라닌 생성을 제어, 억제할 수 있으며, 기존의 미백제에비하여 훨씬 우수한 효과를 나타낼 뿐 아니라 미백제품으로의 적용 범위가 넓다는것을 발견하고 본 발명을 완성하였다.Therefore, the present inventors have tried to develop a whitening cosmetic composition that can exhibit a whitening effect more effectively than a substance that inhibits only the activity of the existing melanin synthase. As a result, allium extract can directly control and inhibit melanin production by directly acting on melanin metabolic pathways induced by α-MSH, showing much better effects than conventional whitening agents and broadening its application to whitening products. It was found and completed the present invention.

따라서, 본 발명의 목적은 자외선에 의해 유발되는 α-MSH의 활성을 억제하여 우수한 미백효과를 나타낼 수 있는 우방자 추출물을 함유하는 미백제를 제공하는데 있다.Accordingly, it is an object of the present invention to provide a whitening agent containing an allergy extract capable of suppressing the activity of α-MSH induced by ultraviolet rays and exhibiting an excellent whitening effect.

도 1은 멜라노사이트에서 멜라닌 합성효소의 발현에 대한 우방자추출물의 저해 효과를 나타내는 도면이다.1 is a diagram showing the inhibitory effect of the allergy extract on the expression of melanin synthase in melanocytes.

본 발명은 우방자추출물을 함유하는 미백제에 관한 것이다.The present invention relates to a whitening agent containing allium extract.

본 발명의 우방자추출물은 미백제 총 건조중량에 대하여 0.0001∼ 50.0 중량%, 바람직하게는 0.005∼ 5.0 중량%의 함량으로 함유된다.Allium extract of the present invention is contained in an amount of 0.0001 to 50.0% by weight, preferably 0.005 to 5.0% by weight based on the total dry weight of the whitening agent.

우방자는 국화과 식물인 우엉의 과실이다. 우엉은 초롱꽃목 국화과의 두해살이풀로 뿌리에 난 잎에는 길이 40㎝의 잎자루가 있으며 잎새는 심장꼴이고 뒷면에 흰 털이 있다. 2년째 또는 3년째 봄에 높이 1.5㎝의 꽃줄기를 뻗고 엉겅퀴와 비슷한 담자색의 꽃이 여러 개 핀다. 야생종은 유럽, 시베리아, 만주 등지에 자생하며, 유럽에서는 간혹 어린 잎과 뿌리를 식용으로 하고, 중국에서는 열매를 이뇨제로 쓰고 있다. 본래 식, 약용식물로 농가에서 옛부터 재배하였고, 길 주변과 산비탈 초지에서 자란다. 늦가을에 채취하고 잡질을 제거하고 햇볕에 말려 그대로 쓴다.Allies are the fruit of burdock, an Asteraceae plant. Burdock is a biennial herb of Asteraceae, with 40 cm long petiole on its root. The leaf is heart shaped with white hairs on the back. In the spring of 2nd or 3rd year, a flower stem 1.5cm in height and several purple flowers like thistle bloom. Wild species grow in Europe, Siberia, and Manchuria. In Europe, young leaves and roots are sometimes eaten, and fruit is used as a diuretic in China. Originally grown as a food and medicinal plant in farmhouses, it grows around roads and on hillsides. Collect it in late autumn, remove the debris and dry it in the sun.

본 발명에서는 상기의 성상에 적합한 우방자를 사용하였다.In the present invention, allies suitable for the above properties were used.

본 발명의 우방자추출물의 제조 방법은 다음과 같다.The manufacturing method of the allergy extract of the present invention is as follows.

우엉의 열매부분을 말린 것을 깨끗한 물로 세척한 다음 건조하여 분말화 하고, 분말화된 우방자의 건조 중량에 대하여 추출 용매로서 물, 저급알코올(메탄올, 에탄올), 물과 저급 알코올의 혼합물, 아세톤, 에틸아세테이트, 1,3-부틸렌 글리콜, 헥산, 디에틸 에테르, 노말 프로판올, 이소-프로판올, 노말-부탄올을 1∼ 15배의 양으로 가해 실온에서 1∼ 15일간 침적시켜 유효 성분을 추출한다. 이렇게 추출한 추출용액을 냉각 콘덴서가 달린 증류 장치를 이용하여 감압농축하여 목적하는 본 발명의 우방자추출물을 얻는다.The dried parts of the burdock are washed with clean water, dried and powdered. The dry weight of the powdered milkybean is extracted with water, lower alcohol (methanol and ethanol), a mixture of water and lower alcohol, acetone and ethyl as extraction solvents. Acetate, 1,3-butylene glycol, hexane, diethyl ether, normal propanol, iso-propanol and normal-butanol are added in an amount of 1 to 15 times, and the active ingredient is extracted by immersion at room temperature for 1 to 15 days. The extraction solution thus extracted is concentrated under reduced pressure using a distillation apparatus equipped with a cooling condenser to obtain the desired mate extract of the present invention.

본 발명의 우방자추출물을 함유하는 미백제는 그 제형에 있어서 특별히 한정되는 바가 없는데, 예를 들면 화장수, 크림, 에센스, 클렌징 폼, 클렌징 워터, 팩 및 보디 오일 등과 같은 기초제품 화장료; 화운데이션, 립스틱, 마스카라, 메이크업 베이스 등과 같은 색조제품 화장료; 및 샴푸, 린스, 헤어콘디셔너, 헤어젤 등과 같은 두발제품 화장료;의 제형을 가질 수 있다.The whitening agent containing the allergy extract of the present invention is not particularly limited in the formulation, for example, cosmetics for basic products such as lotion, cream, essence, cleansing foam, cleansing water, pack and body oil; Color cosmetics such as foundation, lipstick, mascara, makeup base, etc .; And hair cosmetics such as shampoos, rinses, hair conditioners, hair gels, and the like.

다음의 실시예, 실험예, 및 제형예들은 본 발명의 내용을 설명하나 본 발명의 내용이 여기에 한정되는 것은 아니다.The following Examples, Experimental Examples, and Formulation Examples illustrate the content of the present invention, but the content of the present invention is not limited thereto.

실시예 1Example 1

정제수로 세척하고 건조시킨 다음 분말화한 우방자 가루 1Kg을 물 5L에 넣고 15∼ 40℃에서 5일간 추출한 후 300메쉬 여과포로 여과하고, 4∼ 15℃에서 7∼ 10일간 방치하여 저온 숙성시킨 후 와트만 2번 여과지로 여과하였다. 이 추출물을 냉각 콘덴서가 달린 증류장치에서 60℃로 감압 농축하고 건조하여 60.4g(건조중량)을 얻었다.After washing with purified water and drying, 1Kg of powdered milk powder was added to 5L of water, extracted for 5 days at 15-40 ° C., filtered through 300 mesh filter cloth, left at 4-15 ° C. for 7-10 days, and then aged at low temperature. It was filtered twice by filter paper. The extract was concentrated under reduced pressure at 60 ° C. in a distillation apparatus equipped with a cooling condenser and dried to obtain 60.4 g (dry weight).

실시예 2Example 2

정제수로 세척하고 건조시킨 다음 분말화한 우방자 가루 1Kg을 10% 에탄올 5L에 넣고 냉각 콘덴서가 달린 추출기에서 3일간 추출한 후 300메쉬 여과포로 여과하고, 4∼ 15℃에서 7∼ 10일간 방치하여 저온 숙성시킨 후 와트만 2번 여과지로 여과하였다. 이 추출물을 냉각 콘덴서가 달린 증류장치에서 60℃로 감압 농축하고 건조하여 78.6g(건조중량)을 얻었다.After washing with purified water and drying, 1Kg of powdered milk powder was added to 5L of 10% ethanol, extracted for 3 days in an extractor equipped with a cooling condenser, filtered through a 300 mesh filter cloth, and left at 4 to 15 ° C for 7 to 10 days to mature at low temperature. After filtration was performed using Whatman No. 2 filter paper. The extract was concentrated under reduced pressure at 60 ° C. in a distillation apparatus equipped with a cooling condenser and dried to obtain 78.6 g (dry weight).

실시예 3∼ 21Examples 3 to 21

하기 표 1 기재의 용매를 사용하여 실시예 2의 방법으로 추출하여 하기 표 1 기재와 같이 건조중량을 얻었다.Using the solvent described in Table 1 below to extract the method of Example 2 to obtain a dry weight as described in Table 1 below.

구분division 용매menstruum 건조중량(단위: g)Dry weight in g 실시예 3Example 3 20% 에탄올20% ethanol 80.580.5 실시예 4Example 4 30% 에탄올30% ethanol 83.183.1 실시예 5Example 5 40% 에탄올40% ethanol 88.488.4 실시예 6Example 6 50% 에탄올50% ethanol 92.792.7 실시예 7Example 7 60% 에탄올60% ethanol 98.698.6 실시예 8Example 8 70% 에탄올70% ethanol 108.1108.1 실시예 9Example 9 80% 에탄올80% ethanol 107.4107.4 실시예 10Example 10 90% 에탄올90% ethanol 107.8107.8 실시예 11Example 11 100% 에탄올100% ethanol 107.3107.3 실시예 12Example 12 80% 메탄올80% methanol 98.798.7 실시예 13Example 13 100% 메탄올100% methanol 99.299.2 실시예 14Example 14 아세톤Acetone 36.836.8 실시예 15Example 15 에틸 아세테이트Ethyl acetate 66.866.8 실시예 16Example 16 50% 1,3-부틸렌 글리콜 수용액50% 1,3-butylene glycol aqueous solution 10.410.4 실시예 17Example 17 헥산Hexane 24.524.5 실시예 18Example 18 디에틸에테르Diethyl ether 20.220.2 실시예 19Example 19 노말-프로판올Normal-propanol 21.721.7 실시예 20Example 20 이소-프로판올Iso-propanol 27.927.9 실시예 21Example 21 노말-부탄올Normal-butanol 19.719.7

실험예 1Experimental Example 1

이미 제조된 우방자추출물의 멜라닌 생성 저해 효과를 측정하였다.The melanin production inhibitory effect of the already prepared allergy extract was measured.

1) 실험 방법1) Experiment Method

우방자추출물은 우방자 파우더를 1,3-부틸렌 글리콜에 고농도로 용해시키고 다시 완충용액에 희석하여 적당한 농도로 조절하여 추출물 시료액으로 만들어 사용하였다. 멜라노사이트는 마우스 유래 B-16 멜라노마(ATCC CRL 6323) 세포주를 구입하여 사용하였다. α-MSH는 10% DMSO(Dimethyl sulfoxide)에 녹여 1mM 용액으로 사용하였다. 멜라노마 세포주를 포도당 4.5 g/L, 10% 혈청 및 1% 항생제가 함유된 DMEM 배지에 접종하여 75㎠ T-플라스크에 37℃에서 배양하였다. 5% CO2조건하에서 24시간 배양한 후, 0.02% EDTA가 함유된 0.05% 트립신(Trypsin)을 처리하여 세포를분리하고 75㎠ T-플라스크에 접종하여 6시간 배양하였다. 이때 세포 수는 1 × 107세포/플라스크이다. 여기에 적당 농도의 우방자추출물과 α-MSH를 MEM 배지에 희석시켜 배양된 멜라노마 세포에 처리하여 37℃에서 5일간 배양하였다. 배양한 후 배지를 수득하여 475nm에서 흡광도를 측정하여 멜라닌 생성 정도를 비교하였다.Allium extract was used to make an allium powder in high concentration in 1,3-butylene glycol, diluted in buffer solution, and then adjusted to an appropriate concentration to make an extract sample solution. Melanosite was used by purchasing a mouse-derived B-16 melanoma (ATCC CRL 6323) cell line. α-MSH was dissolved in 10% DMSO (dimethyl sulfoxide) and used as a 1 mM solution. Melanoma cell lines were inoculated in DMEM medium containing 4.5 g / L glucose, 10% serum and 1% antibiotics and incubated at 37 ° C. in a 75 cm 2 T-flask. After 24 hours of incubation under 5% CO 2 conditions, cells were treated with 0.05% Trypsin containing 0.02% EDTA, inoculated in a 75 cm 2 T-flask and incubated for 6 hours. Wherein the cell number is 1 × 10 7 cells / flask. Allium extract and α-MSH of appropriate concentration were diluted in MEM medium and treated with cultured melanoma cells and cultured at 37 ° C. for 5 days. After incubation, the medium was obtained and the absorbance was measured at 475 nm to compare the melanin production.

2) 실험 결과2) Experiment result

우방자추출물의 멜라닌 생성 저해 효과를 표 2에 나타내었다.Table 2 shows the melanin production inhibitory effect of allium extract.

추출물extract 멜라닌생성저해효과(%)Melanin inhibitory effect (%) 실험농도(㎍/㎖)Experimental concentration (㎍ / ㎖) 6060 100100 140140 180180 실시예 1Example 1 9.49.4 24.224.2 30.330.3 51.951.9 실시예 2Example 2 10.510.5 27.427.4 33.233.2 55.455.4 실시예 3Example 3 12.112.1 30.930.9 36.736.7 56.356.3 실시예 4Example 4 14.714.7 33.833.8 39.439.4 58.158.1 실시예 5Example 5 16.216.2 36.236.2 41.541.5 61.761.7 실시예 6Example 6 17.417.4 37.537.5 42.142.1 62.562.5 실시예 7Example 7 18.818.8 38.138.1 44.644.6 63.863.8 실시예 8Example 8 19.219.2 38.238.2 45.045.0 64.164.1 실시예 9Example 9 18.418.4 37.537.5 44.744.7 63.563.5 실시예 10Example 10 18.218.2 36.336.3 43.943.9 62.862.8 실시예 11Example 11 18.118.1 33.433.4 41.541.5 60.860.8 실시예 12Example 12 17.517.5 32.632.6 40.340.3 58.558.5 실시예 13Example 13 18.318.3 35.735.7 43.243.2 61.961.9 실시예 14Example 14 7.37.3 15.115.1 17.817.8 30.830.8 실시예 15Example 15 9.39.3 20.420.4 24.524.5 35.435.4 실시예 16Example 16 9.59.5 21.421.4 26.326.3 36.736.7 실시예 17Example 17 8.68.6 19.519.5 22.622.6 35.235.2 실시예 18Example 18 5.95.9 17.817.8 22.322.3 34.134.1 실시예 19Example 19 6.16.1 19.419.4 21.021.0 33.733.7 실시예 20Example 20 9.49.4 22.422.4 24.824.8 31.731.7 실시예 21Example 21 10.110.1 22.622.6 26.126.1 35.935.9

* 상기 값은 3회 실시 평균값임* The above value is the average of 3 runs

우방자추출물들은 대부분 높은 저해 효과를 나타내었으며, 특히 실시예 8의70% 에탄올 추출물에서 가장 높은 저해효과를 가지고 있었다. 에탄올 및 메탄올을 추출용매로 사용한 실시예 1~ 13의 경우가 다른 용매를 사용한 실시예 보다 멜라닌 생성 억제 효과를 가지는 물질들의 용출이 상대적으로 높아, 에탄올 및 메탄올로 추출한 실시예에서 상대적으로 높은 저해효과를 나타내었다.Allium extracts showed the highest inhibitory effect, and especially the 70% ethanol extract of Example 8 had the highest inhibitory effect. In Examples 1 to 13 using ethanol and methanol as extraction solvents, the elution of substances having a melanin inhibitory effect was higher than those using other solvents. Indicated.

실험예 2Experimental Example 2

멜라노사이트에서 멜라닌 합성효소의 발현 억제 효과를 측정하였다.The inhibitory effect of melanin synthase on melanocytes was measured.

1) 실험방법1) Experiment Method

멜라노사이트는 마우스 유래 B-16 멜라노마(ATCC CRL 6323) 세포주를 구입하여 사용하였다. α-MSH는 10% DMSO(Dimethyl sulfoxide)에 녹여 1mM 용액으로 사용하였다. 멜라노마 세포주를 포도당 4.5 g/L, 10% 혈청 및 1% 항생제가 함유된 DMEM 배지에 접종하여 75㎠ T-플라스크에 37℃에서 배양하였다. 5% CO2조건하에서 24시간 배양한 후, 0.02% EDTA가 함유된 0.05% 트립신(Trypsin)을 처리하여 세포를 분리하고 75㎠ T-플라스크에 접종하여 6시간 배양하였다. 이때 세포 수는 1 × 107세포/플라스크이다. 여기에 적당 농도의 우방자추출물과 α-MSH를 MEM 배지에 희석시켜 표 3에 기재한 조건으로 배양된 멜라노마 세포에 각각 처리하여 37℃에서 5일간 배양하였다. 배양한 후 세포를 0.02% EDTA가 함유된 0.05% 트립신(Trypsin)을 처리하여 세포를 분리한 후 5분간 원심 분리하여 세포만을 수집하였다. 수집된 세포를 0.1% 트리톤-엑스 100(Triton-X 100)으로 분쇄한 후, 10% 트리스-글리신 겔(Tris-Glycine gel)에서 전기영동하고 0.2% 도파(DOPA) 용액으로 염색하여 멜라닌 합성효소의 생성 정도를 비교하였다.Melanosite was used by purchasing a mouse-derived B-16 melanoma (ATCC CRL 6323) cell line. α-MSH was dissolved in 10% DMSO (dimethyl sulfoxide) and used as a 1 mM solution. Melanoma cell lines were inoculated in DMEM medium containing 4.5 g / L glucose, 10% serum and 1% antibiotics and incubated at 37 ° C. in a 75 cm 2 T-flask. After 24 hours of incubation under 5% CO 2 conditions, cells were treated with 0.05% Trypsin containing 0.02% EDTA, inoculated in a 75 cm 2 T-flask and incubated for 6 hours. Wherein the cell number is 1 × 10 7 cells / flask. Here, the appropriate concentration of allium extract and α-MSH were diluted in MEM medium, and treated with melanoma cells incubated under the conditions shown in Table 3, followed by incubation at 37 ° C. for 5 days. After incubation, the cells were treated with 0.05% trypsin containing 0.02% EDTA to separate the cells, followed by centrifugation for 5 minutes to collect only the cells. The collected cells were triturated with 0.1% Triton-X 100, then electrophoresed on 10% Tris-Glycine gel and stained with 0.2% DOPA solution for melanin synthase. The degree of formation of was compared.

우방자추출물 첨가량 (㎍/㎖)Allium extract added (㎍ / ㎖) α-MSH 첨가량(nM)α-MSH addition amount (nM) 세포 1Cell 1 00 00 세포 2Cells 2 00 100100 세포 3Cell 3 100100 00 세포 4Cell 4 100100 100100

2)실험결과2) Experiment result

실험 결과는 도 1에 나타낸 바와 같다.The experimental result is as shown in FIG.

도 1에서 각각의 lane은 그 순서대로 세포 1, 세포 2, 세포 3 및 세포 4을 나타낸다.Each lane in Figure 1 represents Cell 1, Cell 2, Cell 3 and Cell 4 in that order.

실험 결과, 세포 (1)에 비해, α-MSH를 처리한 세포 (2)의 티로시아나제 단백질량이 증가하였고, α-MSH와 우방자추출물을 함께 처리한 세포 (4)의 경우 α-MSH만을 처리한 세포 (2)보다 티로시나아제 단백질량이 크게 감소하였다. 따라서, 우방자추출물은 α-MSH 처리에 의한 티로시나아제 단백질의 증가를 억제함을 알 수 있다.As a result, compared with the cell (1), the amount of tyrosianase protein of the cell (2) treated with α-MSH was increased, and only the α-MSH was used for the cell (4) treated with both α-MSH and allergy extract. The amount of tyrosinase protein was significantly reduced compared to the treated cells (2). Therefore, it can be seen that the sperm extract inhibits the increase of tyrosinase protein by α-MSH treatment.

실험예 3Experimental Example 3

이미 제조된 우방자추출물의 피브로블라스트(fibroblast) 세포에 대한 독성 여부를 측정하였다.Toxicity of fibroblast cells of the prepared ovarian extract was measured.

1) 실험 방법1) Experiment Method

피브로블라스트 세포는 마우스 유래 NIH/3T3(ATCC CRL 1658) 세포주를 구입하여 사용하였다. 피브로블라스트 세포주를 포도당 4.5 g/L, 10% 혈청 및 1% 항생제가 함유된 DMEM 배지에 접종하여 75㎠ T-플라스크에 37℃에서 배양한다. 5% CO2조건하에서 24시간 배양한 후, 0.02% EDTA가 함유된 0.05% 트립신(Trypsin)을 처리하여 세포를 분리한 후 96-웰-플라스크에 접종하여 6시간 배양하였다. 이때 세포 수는 1 × 104세포/웰이다. 여기에 적당 농도의 우방자추출물을 첨가하여 12시간 배양하였다. 배양한 후, MTT(3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolin bromide) 용액(5㎎/㎖)을 웰에 10㎕ 첨가하여 4시간 배양하고, DMSO(Dimethyl sulfoxide) 용액 100㎕를 첨가한 후, OD 570nm에서 흡광도를 측정하여 세포의 생존율을 비교하였다.Fibroblast cells were purchased from a mouse-derived NIH / 3T3 (ATCC CRL 1658) cell line. Fibroblast cell lines are inoculated in DMEM medium containing 4.5 g / L glucose, 10% serum and 1% antibiotic and incubated at 37 ° C. in a 75 cm 2 T-flask. After incubation for 24 hours under 5% CO 2 condition, cells were isolated by treatment with 0.05% Trypsin containing 0.02% EDTA, and then inoculated in a 96-well-flask and incubated for 6 hours. Wherein the cell number is 1 × 10 4 cells / well. An allium extract of an appropriate concentration was added thereto and incubated for 12 hours. After incubation, 10 μl of MTT (3- (4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolin bromide) solution (5 mg / ml) was added to the wells and incubated for 4 hours, followed by DMSO (dimethyl sulfoxide). ) 100 μl of the solution was added, and then the absorbance was measured at 570 nm to compare the viability of the cells.

2) 실험결과2) Experiment result

실험 결과는 표 4에 나타내었다.The experimental results are shown in Table 4.

우방자추출물의 농도(㎍/㎖)Concentrate of Allium Extracts (㎍ / ㎖) 생존율(%)Survival rate (%) 2020 81.981.9 6060 75.575.5 100100 86.186.1 140140 88.388.3 180180 82.882.8

- 세포에 대한 독성 판정-Determination of toxicity to cells

생존률 70% 이하 - 중독성,Survival below 70%-addictive,

70% 초과 80% 이하 - 경독성,Greater than 70% and less than 80%-mild toxicity,

80% 초과 90% 이하 - 미독성,Greater than 80% and less than 90%-non-toxic,

90% 초과 - 무독성Over 90%-non-toxic

이상의 실험결과, 우방자 추출물 첨가 배양시 대부분 미독성으로 세포자극이 거의 없는 것으로 나타났다.As a result of the above experiment, it was found that the cell stimulation was almost non-toxic in the culture of the addition of the allergy extract.

이하 상기한 실험예들의 결과를 근거로 하여 실시예 8에서의 우방자추출물을 함유하는 화장료를 조성하여 제시한다. 그러나, 본발명의 조성물을 하기의 제형예들로 한정하고자 하는 것은 아니다.Hereinafter, based on the results of the above experimental examples, to present a cosmetic composition containing the allergy extract in Example 8. However, it is not intended to limit the composition of the present invention to the following formulation examples.

제형예 1. 유연화장수(스킨로션)Formulation Example 1 Softening Cosmetic (Skin Lotion)

하기의 표와 같이 우방자 추출물을 함유하는 유연화장수를 통상의 방법에 따라 제조하였다.As shown in the following table, the softening lotion containing the alligator extract was prepared according to a conventional method.

성분ingredient 함량(단위:중량%)Content (unit: weight%) 우방자 추출물Ally extract 1.01.0 글리세린glycerin 5.05.0 1,3-부틸렌글리콜1,3-butylene glycol 3.03.0 피이지 1500Fiji 1500 1.01.0 알란토인Allantoin 0.10.1 DL-판테놀DL-panthenol 0.30.3 이.디.티.에이-2NaE.T.A.-2Na 0.020.02 벤조페논-9Benzophenone-9 0.040.04 소듐 히아루로네이트Sodium hyaluronate 5.05.0 에탄올ethanol 10.010.0 옥틱도데세스-16Octicdodeceth-16 0.20.2 폴리솔베이트 20Polysorbate 20 0.20.2 incense 0.020.02 유니사이드-유13Uniside-Y13 0.010.01 그린 #3Green # 3 0.0010.001 증류수Distilled water 잔량Remaining amount 합계Sum 100100

제형예 2. 수렴화장수Formulation Example 2. Converging Cosmetic Water

하기의 표와 같이 우방자 추출물을 함유하는 수렴화장수를 통상의 방법에 따라 제조하였다.As shown in the following table, astringent cosmetics containing allium extract were prepared according to a conventional method.

성분ingredient 함량(단위:중량%)Content (unit: weight%) 우방자 추출물Ally extract 1.01.0 글리세린glycerin 2.02.0 1,3-부틸렌글리콜1,3-butylene glycol 2.02.0 알란토인Allantoin 0.20.2 DL-판테놀DL-panthenol 0.20.2 이.디.티.에이-2NAE.T.A.-2NA 0.020.02 벤조페논-9Benzophenone-9 0.040.04 소듐 히아루로네이트Sodium hyaluronate 3.03.0 에탄올ethanol 15.015.0 폴리솔베이트Polysorbate 0.30.3 위치하겔 추출물Witch Hagel Extract 2.02.0 구연산Citric acid 미량a very small amount incense 0.020.02 유니사이드-유13Uniside-Y13 0.010.01 그린 #3Green # 3 0.0010.001 증류수Distilled water 잔량Remaining amount 합계Sum 100100

제형예 3. 영양화장수Formulation Example 3. Nutrients

하기의 표와 같이 우방자 추출물을 함유하는 영양화장수를 통상의 방법에 따라 제조하였다.As shown in the following table, nutritious longevity containing allium extract was prepared according to a conventional method.

성분ingredient 함량(단위:중량%)Content (unit: weight%) 우방자추출물Allies Extract 3.03.0 글리세릴 스테아레이트 SEGlyceryl Stearate SE 1.51.5 스테아릴알콜Stearyl alcohol 1.51.5 라놀린lanolin 1.51.5 폴리솔베이트 60Polysorbate 60 1.31.3 솔비탄스테아레이트Sorbitan stearate 0.50.5 경화식물유Cured Vegetable Oil 1.01.0 광물유Mineral oil 5.05.0 스쿠알란Squalane 3.03.0 트리옥타노인Trioctanoine 2.02.0 디메치콘Dimethicone 0.80.8 초산토코페롤Tocopherol Acetate 0.50.5 카르복시비닐폴리머Carboxy Vinyl Polymer 0.120.12 글리세린glycerin 5.05.0 1,3-부틸렌글리콜1,3-butylene glycol 3.03.0 소듐히아루로네이트Sodium hyaluronate 5.05.0 트리에탄올아민Triethanolamine 0.120.12 incense 0.010.01 유니사이드-유13Uniside-Y13 0.020.02 그린 #3Green # 3 0.0030.003 증류수Distilled water 잔량Remaining amount 합계Sum 100100

제형예 4. 영양크림Formulation Example 4. Nutrition Cream

하기의 표와 같이 우방자 추출물을 함유하는 영양크림을 통상의 방법에 따라 제조하였다.Nutritious cream containing allergy extract as shown in the following table was prepared according to a conventional method.

성분ingredient 함량(단위:중량%)Content (unit: weight%) 우방자추출물Allies Extract 3.03.0 친유형 모노스테아린산글리세린Lipophilic monostearate 2.02.0 세테아릴알콜Cetearyl Alcohol 2.22.2 스테아린산Stearic acid 1.51.5 밀납Beeswax 1.01.0 폴리솔베이트 60Polysorbate 60 1.51.5 솔비탄스테아레이트Sorbitan stearate 0.60.6 경화식물류Cured Plants 1.01.0 스쿠알란Squalane 3.03.0 광물유Mineral oil 5.05.0 트리옥타노인Trioctanoine 5.05.0 디메치콘Dimethicone 1.01.0 소듐마그네슘실리케이트Sodium magnesium silicate 0.10.1 글리세린glycerin 5.05.0 베타인Betaine 3.03.0 트리에탄올아민Triethanolamine 1.01.0 소듐히아루로네이트Sodium hyaluronate 4.04.0 incense 0.010.01 유니사이드-유13Uniside-Y13 0.020.02 그린 #3Green # 3 0.0030.003 증류수Distilled water 잔량Remaining amount 합계Sum 100100

제형예 5. 맛사지크림Formulation Example 5. Massage Cream

하기의 표와 같이 우방자 추출물을 함유하는 맛사지크림을 통상의 방법에 따라 제조하였다.Massage creams containing the allergy extract as shown in the following table were prepared according to a conventional method.

성분ingredient 함량(단위:중량%)Content (unit: weight%) 우방자 추출물Ally extract 3.03.0 친유형 모노스케아린산 글리세린Lipophilic monostearic acid glycerin 1.51.5 스테아릴알콜Stearyl alcohol 1.51.5 스테아린산Stearic acid 1.01.0 폴리솔베이트 60Polysorbate 60 1.51.5 솔비탄스테아레이트Sorbitan stearate 0.60.6 이소스테아릴이소스테레이트Isostearyl Isosterate 5.05.0 스쿠알란Squalane 5.05.0 광물유Mineral oil 35.035.0 디메치콘Dimethicone 0.50.5 히드록시에틸실룰로오스Hydroxyethyl cellulose 0.120.12 글리세린glycerin 6.06.0 트리에탄올아민Triethanolamine 0.70.7 incense 0.010.01 유니사이드-유13Uniside-Y13 0.020.02 그린 #3Green # 3 0.0030.003 증류수Distilled water 잔량Remaining amount 합계Sum 100100

제형예 6. 에센스Formulation Example 6. Essence

하기의 표와 같이 우방자 추출물을 함유하는 에센스를 통상의 방법에 따라 제조하였다.Essences containing allium extract as shown in the following table were prepared according to a conventional method.

성분ingredient 함량(단위:중량%)Content (unit: weight%) 우방자추출물Allies Extract 3.03.0 글리세린glycerin 10.010.0 베타인Betaine 5.05.0 피이지 1500Fiji 1500 2.02.0 알란토인Allantoin 0.10.1 DL-판테놀DL-panthenol 0.30.3 이.디.티.에이-2NaE.T.A.-2Na 0.020.02 벤조페논-9Benzophenone-9 0.040.04 히드록시에틸 셀룰로오스Hydroxyethyl cellulose 0.10.1 소듐히아루로네이트Sodium hyaluronate 8.08.0 카르복시비닐폴리머Carboxy Vinyl Polymer 0.20.2 트리에탄올아민Triethanolamine 0.180.18 옥틸도데칸올Octyldodecanol 0.30.3 옥틸도데세스-16Octyldodeceth-16 0.40.4 에탄올ethanol 6.06.0 incense 0.020.02 유니사이드-유13Uniside-Y13 0.010.01 그린 #3Green # 3 0.0010.001 증류슈Distilled shoe 잔량Remaining amount 합계Sum 100100

제형예 7. 팩Formulation Example 7 Pack

하기의 표와 같이 우방자 추출물을 함유하는 팩을 통상의 방법에 따라 제조하였다.As shown in the following table, a pack containing the alligator extract was prepared according to a conventional method.

성분ingredient 함량(단위:중량%)Content (unit: weight%) 우방자추출물Allies Extract 1.01.0 폴리비닐알콜Polyvinyl alcohol 15.015.0 셀룰로오스검Cellulose gum 0.150.15 글리세린glycerin 3.03.0 피이지 1500Fiji 1500 2.02.0 사이크로데스트린Cyclodextrin 0.150.15 DL-판테놀DL-panthenol 0.40.4 알란토인Allantoin 0.10.1 글리시리진산모노암모늄Monomethylammonium Glycyric Acid 0.30.3 니코틴아미드Nicotinamide 0.50.5 에탄올ethanol 6.06.0 피이지 40 경화피마자유Fiji 40 Cured Castor Oil 0.30.3 incense 0.010.01 유니사이드-유13Uniside-Y13 0.020.02 그린 #3Green # 3 0.0030.003 증류수Distilled water 잔량Remaining amount 합계Sum 100100

본 발명의 우방자 추출물을 함유하는 미백제는 α-MSH에 의해 유발되는 멜라닌 대사 경로에 직접 작용함으로써, 멜라닌 생성을 제어, 억제하여 우수한 미백효과를 나타낼 뿐 아니라, 미백제품으로의 적용 범위가 넓다.The whitening agent containing the alligator extract of the present invention acts directly on the melanin metabolic pathway induced by α-MSH, thereby controlling and inhibiting melanin production, thereby exhibiting excellent whitening effect, and a wide range of application to whitening products.

Claims (4)

우방자추출물을 함유하는 미백제.Whitening agent containing allergy extract. 제 1항에 있어서, 우방자추출물이 화장료의 건조중량에 대하여 0.0001∼ 50.0 중량%의 함량으로 함유되는 것을 특징으로 하는 미백제.The whitening agent according to claim 1, wherein the allium extract is contained in an amount of 0.0001 to 50.0% by weight based on the dry weight of the cosmetic. 제 1항에 있어서, 우방자추출물이 분말화한 우방자를 물, 저급알코올(메탄올, 에탄올), 물과 저급 알코올의 혼합물, 아세톤, 에틸아세테이트, 1,3-부틸렌 글리콜, 헥산, 디에틸 에테르, 노말 프로판올, 이소-프로판올, 노말-부탄올 중에서 선택된 추출 용매에 가하고 실온에서 1∼ 15일간 침적시켜 유효 성분을 추출한 후, 그 추출용액을 냉각 콘덴서가 달린 증류 장치를 이용하여 감압농축하는 추출방법에 의해 얻어짐을 특징으로 하는 미백제.The method according to claim 1, wherein the allium extract powdered allium extract is water, lower alcohol (methanol, ethanol), a mixture of water and lower alcohol, acetone, ethyl acetate, 1,3-butylene glycol, hexane, diethyl ether, It is added to an extraction solvent selected from normal propanol, iso-propanol, and normal-butanol, and the active ingredient is extracted by immersion at room temperature for 1 to 15 days, and then the extraction solution is concentrated under reduced pressure using a distillation apparatus equipped with a cooling condenser. Whitening agent characterized by being obtained. 제 1항에 있어서, 제형이 기초제품 화장료, 색조제품 화장료 및 두발제품 화장료임을 특징으로 하는 미백제.The whitening agent according to claim 1, wherein the formulation is a basic cosmetic, a color cosmetic and a hair cosmetic.
KR1020000076871A 2000-12-15 2000-12-15 Skin whitening composition containing arctium lappa extracts KR20020046615A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020000076871A KR20020046615A (en) 2000-12-15 2000-12-15 Skin whitening composition containing arctium lappa extracts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020000076871A KR20020046615A (en) 2000-12-15 2000-12-15 Skin whitening composition containing arctium lappa extracts

Publications (1)

Publication Number Publication Date
KR20020046615A true KR20020046615A (en) 2002-06-21

Family

ID=27682138

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020000076871A KR20020046615A (en) 2000-12-15 2000-12-15 Skin whitening composition containing arctium lappa extracts

Country Status (1)

Country Link
KR (1) KR20020046615A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053680A1 (en) * 2003-12-03 2005-06-16 Beiersdorf Ag Combination of 2,3-dibenzylbutyrolactone and licochalcone-a
KR100619459B1 (en) * 2006-05-22 2006-09-07 대건엔지니어링(주) Floodgate for waterways
KR101258991B1 (en) * 2011-04-29 2013-04-26 그린텍이십일 주식회사 Preparation method of arctigenin including fermentation of microorganism in medium containing arctium lappa l.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990079378A (en) * 1998-04-04 1999-11-05 서경배 Cosmetics containing natural products that are effective in treating and preventing acne
KR20000045575A (en) * 1998-12-30 2000-07-25 유상옥 Antioxidant cosmetic composition containing the seed extract of arctium lappa
JP2000290162A (en) * 1999-04-06 2000-10-17 Nisshin Oil Mills Ltd:The Cosmetic

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990079378A (en) * 1998-04-04 1999-11-05 서경배 Cosmetics containing natural products that are effective in treating and preventing acne
KR20000045575A (en) * 1998-12-30 2000-07-25 유상옥 Antioxidant cosmetic composition containing the seed extract of arctium lappa
JP2000290162A (en) * 1999-04-06 2000-10-17 Nisshin Oil Mills Ltd:The Cosmetic

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053680A1 (en) * 2003-12-03 2005-06-16 Beiersdorf Ag Combination of 2,3-dibenzylbutyrolactone and licochalcone-a
KR100619459B1 (en) * 2006-05-22 2006-09-07 대건엔지니어링(주) Floodgate for waterways
KR101258991B1 (en) * 2011-04-29 2013-04-26 그린텍이십일 주식회사 Preparation method of arctigenin including fermentation of microorganism in medium containing arctium lappa l.

Similar Documents

Publication Publication Date Title
KR101971837B1 (en) Cosmetic composition for improving skin whitening and wrinkle comprising adventitious root extract of Centella asiatica as effective component
KR20150139688A (en) The Extract Of The Citrus grandis Osbeck Having Skin Whitening Activity And Cosmetic Composition Containing The Same
KR101773456B1 (en) Method for preparing complex fermented extract of crude drugs and cosmetic composition comprising the same
KR20090056521A (en) Cosmetic composition for skin-aging protection and wrinkle improvement comprising the extract of nephelium lappaceum and litchi chinensis sonn as active ingredient
KR102032873B1 (en) Antioxidant and moisturizing cosmetic composition
KR101525873B1 (en) Cosmetic composition containing Manufacturing method and Cultured wild Ginseng Roots, Hedysarum ussuriensis, Sophora flavescens and Adenophora triphylla by two-stage fermentation for improving skin
KR20120003238A (en) Composition of skin external application for skin whitening containing extract of flower and fruit of broussonetia kazinoki
KR100441596B1 (en) cosmetic composition containing plant extract complex
KR100638056B1 (en) Skin whitening composition containing the fruit extracts of forsythia suspensa
KR20200009195A (en) A cosmetic composition comprising ligustrum lucidum extract
KR102612017B1 (en) Composition for skin improvement comprising multiple extract
KR20170136969A (en) Method for preparing natural extract using sugars
KR100914963B1 (en) Composition for skin whitening comprising the extract of angelica dahurica, prunus mume, pinellia ternata, and artemisiae anomalae
KR102632084B1 (en) Cosmetic composition for anti-oxidation, skin whitening, and improving of skin wrinkle containing Sanguisorba officinalis extract
KR20020046615A (en) Skin whitening composition containing arctium lappa extracts
KR100789634B1 (en) Cosmetic for skin whitening containing a herb extract with inhibitory activity of melanin formation
KR20100088463A (en) Cosmetic composition for whitening the skin comprising the extract of aronia melanocarpa as active ingredient
KR100467501B1 (en) A cosmetic composite
KR101695781B1 (en) A composition for antioxidating, whitening and improving wrinkle comprising extracts of nursery spiraea
KR102223368B1 (en) Cosmetic composition for skin
KR102567315B1 (en) Cosmetic composition for gray hair containing fermented extracts of natural ingredients
KR20010110001A (en) Cosmetics composition containing Psoralea corylifolia L. extracts
KR102119823B1 (en) A cosmetic composition comprising morus bombycis extract
KR102006665B1 (en) Anti-oxidant, anti-inflammatory, whitening and moisturizing cosmetic composition comprising the mixed herbal extract of silver weed, heather, and milk thistle as an active ingredient and preparation method of the same
KR102412907B1 (en) Composition for skin whitening and improving skin wrinkle comprising Codonopsis lanceolata bud extract as an active ingredient

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application